Resistance of mitochondrial p53 to dominant inhibition

Molecular Cancer

Volumn 7, Issue , 2008, Pages

  Heyne, Kristina ^a   Schmitt, Katrin ^a   Mueller, Daniel ^a   Armbruester, Vivienne ^a   Mestres, Pedro ^a   Roemer, Klaus ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRIAL PROTEIN; MUTANT PROTEIN; PROTEIN P53; PROTEIN P73; ALPHA AMANITIN; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DNA BINDING PROTEIN; ETOPOSIDE; FLUOROURACIL; NUCLEAR PROTEIN; TP53 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL NUCLEUS; CELL STRAIN HCT116; CELL STRESS; CONTROLLED STUDY; GENE DUPLICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; WILD TYPE; CELL PROLIFERATION; COLON TUMOR; DOMINANT GENE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MITOCHONDRION; MUTATION; PATHOLOGY; PROMOTER REGION; PROTEIN BINDING; TIME; TRANSACTIVATION;

ALPHA-AMANITIN; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA-BINDING PROTEINS; ETOPOSIDE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, DOMINANT; HCT116 CELLS; HUMANS; MITOCHONDRIA; MUTATION; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; TIME FACTORS; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 46349083468     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-7-54     Document Type: Article

References (51)

1. Vousden KH Lane DP p53 in health and disease Nat Rev Mol Cell Biol 2007, 8:275-283 10.1038/nrm2147 17380161
2. Moll UM Wolff S Speidel D Deppert W Transcription-independent pro-apoptotic functions of p53 Curr Opin Cell Biol 2005, 17 631 6. Epub 2005 Oct 13. 10.1016/j.ceb.2005.09.007 16226451
3. Chipuk JE Green DR Dissecting p53-dependent apoptosis Cell Death Differ 2006, 13:994-1002 10.1038/sj.cdd.4401908 16543937
4. Jeffers JR Parganas E Lee Y Yang C Wang J Brennan J MacLean KH Han J Chittenden T Ihle JN McKinnon PJ Cleveland JL Zambetti GP Puma is an essential mediator of p53-dependent and -independent apoptotic pathways Cancer Cell 2003, 4:321-328 10.1016/S1535-6108(03)00244-7 14585359
5. Villunger A Michalak EM Coultas L Mullauer F Bock G Ausserlechner MJ Adams JM Strasser A p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa Science 2003, 302:1036 8. Epub 2003 Sep 18. 10.1126/science.1090072 14500851
6. Arima Y Nitta M Kuninaka S Zhang D Fujiwara T Taya Y Nakao M Saya H Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria J Biol Chem 2005, 280:19166-76. Epub 2005 Mar 7. 10.1074/jbc.M410691200 15753095
7. Mihara M Erster S Zaika A Petrenko O Chittenden T Pancoska P Moll UM p53 has a direct apoptogenic role at the mitochondria Mol Cell 2003, 11:577-590 10.1016/S1097-2765(03)00050-9 12667443
8. Tomita Y Marchenko N Erster S Nemajerova A Dehner A Klein C Pan H Kessler H Pancoska P Moll UM WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization J Biol Chem 2006, 281:8600-6. Epub 2006 Jan 26. 10.1074/ jbc.M507611200 16443602
9. Marchenko ND Zaika A Moll UM Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling J Biol Chem 2000, 275:16202-16212 10.1074/jbc.275.21.16202 10821866
10. Sansome C Zaika A Marchenko ND Moll UM Hypoxia death stimulus induces translocation of p53 protein to mitochondria. Detection by immunofluorescence on whole cells FEBS Lett 2001, 488:110-115 10.1016/ S0014-5793(00)02368-1 11163756
11. Dumont P Leu JI Della Pietra AC 3rd George DL Murphy M The codon 72 polymorphic variants of p53 have markedly different apoptotic potential Nat Genet 2003, 33:357-65. Epub 2003 Feb 3. 10.1038/ng1093 12567188
12. Leu JI Dumont P Hafey M Murphy ME George DL Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex Nat Cell Biol 2004, 6:443-50. Epub 2004 Apr 11. 10.1038/ncb1123 15077116
13. Erster S Mihara M Kim RH Petrenko O Moll UM In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation Mol Cell Biol 2004, 24:6728-6741 444865 15254240 10.1128/MCB.24.15.6728-6741.2004
14. Zhao Y Chaiswing L Velez JM Batinic-Haberle I Colburn NH Oberley TD St Clair DK p53 translocation to mitochondria precedes its nuclear translocation and targets mitochondrial oxidative defense protein-manganese superoxide dismutase Cancer Res 2005, 65:3745-3750 10.1158/0008-5472.CAN-04-3835 15867370
15. Chipuk JE Kuwana T Bouchier-Hayes L Droin NM Newmeyer DD Schuler M Green DR Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis Science 2004, 303:1010-1014 10.1126/ science.1092734 14963330
16. Chipuk JE Bouchier-Hayes L Kuwana T Newmeyer DD Green DR PUMA couples the nuclear and cytoplasmic proapoptotic function of p53 Science 2005, 309:1732-1735 10.1126/science.1114297 16151013
17. Li Y Prives C Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 2007, 26:2220-2225 10.1038/ sj.onc.1210311 17401431
18. Roemer K Mutant p53: Gain-of-function oncoproteins and wild-type p53 inactivators Biol Chem 1999, 380:879-887 10.1515/BC.1999.108 10494837
19. Iwakuma T Lozano G Crippling p53 activities via knock-in mutations in mouse models Oncogene 2007, 26:2177-2184 10.1038/sj.onc.1210278 17401426
20. Miller FD Kaplan DR To die or not to die: Neurons and p63 Cell Cycle 2007. 6:312-7. Epub 2007 Feb 3. 17264677
21. Stiewe T Theseling CC Putzer BM Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: Implications for tumorigenesis J Biol Chem 2002, 277:14177-85. Epub 2002 Feb 13. 10.1074/ jbc.M200480200 11844800
22. Bunz F Dutriaux A Lengauer C Waldman T Zhou S Brown JP Sedivy JM Kinzler KW Vogelstein B Requirement for p53 and p21 to sustain G2 arrest after DNA damage Science 1998. 282:1497-1501 10.1126/science.282.5393.1497 9822382
23. Bunz F Hwang PM Torrance C Waldman T Zhang Y Dillehay L Williams J Lengauer C Kinzler KW Vogelstein B Disruption of p53 in human cancer cells alters the responses to therapeutic agents J Clin Invest 1999, 104:263-269 408422 10430607 10.1172/JCI6863
24. Kaeser MD Pebernard S Iggo RD Regulation of p53 stability and function in HCT116 colon cancer cells J Biol Chem 2004, 279:7598-605. Epub 2003 Dec 9. 10.1074/jbc.M311732200 14665630
25. Mahyar-Roemer M Fritzsche C Wagner S Laue M Roemer K Mitochondrial p53 levels parallel total p53 levels independent of stress response in human colorectal carcinoma and glioblastoma cells Oncogene 2004, 23:6226-6236 10.1038/sj.onc.1207637 15247902
26. Frazier MW He X Wang J Gu Z Cleveland JL Zambetti GP Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain Mol Cell Biol 1998, 18:3735-3743 108956 9632756
27. Lanyi A Deb D Seymour RC Ludes-Meyers JH Subler MA Deb S 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain Oncogene 1998, 16:3169-3176 10.1038/sj.onc.1201857 9671396
28. Mahyar-Roemer M Roemer K p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents Oncogene 2001, 20:3387-3398 10.1038/sj.onc.1204440 11423989
29. Shaulian E Zauberman A Ginsberg D Oren M Identification of a minimal transforming domain of p53: Negative dominance through abrogation of sequence-specific DNA binding Mol Cell Biol 1992, 12:5581-5592 360497 1448088
30. Gottlieb E Haffner R von Ruden T Wagner EF Oren M Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal EMBO J 1994, 13:1368-1374 394954 8137820
31. Sheard MA Uldrijan S Vojtesek B Role of p53 in regulating constitutive and X-radiation-inducible CD95 expression and function in carcinoma cells Cancer Res 2003, 63:7176-7184 14612511
32. Cui R Widlund HR Feige E Lin JY Wilensky DL Igras VE D'Orazio J Fung CY Schanbacher CF Granter SR Fisher DE Central role of p53 in the suntan response and pathologic hyperpigmentation Cell 2007, 128:853-864 10.1016/ j.cell.2006.12.045 17350573
33. Jiang P Du W Heese K Wu M The Bad Guy Cooperates with Good Cop p53: Bad Is Transcriptionally Up-Regulated by p53 and Forms a Bad/p53 Complex at the Mitochondria To Induce Apoptosis Mol Cell Biol 2006, 26:9071-82. Epub 2006 Sep 25. 1636833 17000778 10.1128/MCB.01025-06
34. Nicholls CD McLure KG Shields MA Lee PW Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect J Biol Chem 2002, 277:12937-45. Epub 2002 Jan 22. 10.1074/jbc.M108815200 11805092
35. Chan WM Siu WY Lau A Poon RY How many mutant p53 molecules are needed to inactivate a tetramer? Mol Cell Biol 2004, 24:3536-3551 381690 15060172 10.1128/MCB.24.8.3536-3551.2004
36. Kitayner M Rozenberg H Kessler N Rabinovich D Shaulov L Haran TE Shakked Z Structural basis of DNA recognition by p53 tetramers Mol Cell 2006, 22:741-753 10.1016/j.molcel.2006.05.015 16793544
37. Sigal A Rotter V Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome Cancer Res 2000, 60:6788-6793 11156366
38. Blagosklonny MV p53 from complexity to simplicity: Mutant p53 stabilization, gain-of-function, and dominant-negative effect FASEB J 2000, 14:1901-1907 10.1096/fj.99-1078rev 11023974
39. Dearth LR Qian H Wang T Baroni TE Zeng J Chen SW Yi SY Brachmann RK Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers Carcinogenesis 2007 28:289-98. Epub 2006 Jul 21. 10.1093/carcin/bgl132 16861262
40. Varley JM Thorncroft M McGown G Appleby J Kelsey AM Tricker KJ Evans DG Birch JM A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene Oncogene 1997, 14:865-871 10.1038/sj.onc.1201041 9047394
41. Birch JM Blair V Kelsey AM Evans DG Harris M Tricker KJ Varley JM Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome Oncogene 1998, 17:1061-1068 10.1038/ sj.onc.1202033 9764816
42. Lang GA Iwakuma T Suh YA Liu G Rao VA Parant JM Valentin-Vega YA Terzian T Caldwell LC Strong LC El-Naggar AK Lozano G Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome Cell 2004, 119:861-872 10.1016/j.cell.2004.11.006 15607981
43. Olive KP Tuveson DA Ruhe ZC Yin B Willis NA Bronson RT Crowley D Jacks T Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome Cell 2004, 119:847-860 10.1016/j.cell.2004.11.004 15607980
44. Venkatachalam S Shi YP Jones SN Vogel H Bradley A Pinkel D Donehower LA Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation EMBO J 1998, 17:4657-4667 1170795 9707425 10.1093/emboj/17.16.4657
45. Palacios G Moll UM Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo Oncogene 2006, 25:6133-9. Epub 2006 May 8. 10.1038/sj.onc.1209641 16682948
46. Lavelle D Chen YH Hankewych M DeSimone J Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression Am J Hematol 2001, 68:170-178 10.1002/ajh.1174 11754398
47. Marston NJ Jenkins JR Vousden KH Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6 Oncogene 1995, 10:1709-1715 7753547
48. Marchenko ND Wolff S Erster S Becker K Moll UM Monoubiquitylation promotes mitochondrial p53 translocation EMBO J 2007, 26:923-34. Epub 2007 Feb 1. 1852828 17268548 10.1038/sj.emboj.7601560
49. Atz J Wagner P Roemer K Function, oligomerization, and conformation of tumor-associated p53 proteins with mutated C-terminus J Cell Biochem 2000, 76:572-584 10.1002/ (SICI)1097-4644(20000315)76:4<572::AID-JCB6>3.0.CO;2-6 10653977
50. Fritzsche C Zeller G Knaup KX Roemer K No anti-apoptotic effects of single copies of mutant p53 genes in drug-treated tumor cells Anticancer Drugs 2004, 15:679-688 10.1097/01.cad.0000136878.96680.f5 15269599
51. Boese A Sauter M Galli U Best B Herbst H Mayer J Kremmer E Roemer K Mueller-Lantzsch N Human endogenous retrovirus protein cORF supports cell transformation and associates with the promyelocytic leukemia zinc finger protein Oncogene 2000, 19:4328-4336 10.1038/sj.onc.1203794 10980608